261 related articles for article (PubMed ID: 30324554)
1. Declining Rates of Referral for Irritable Bowel Syndrome Without Constipation at a Tertiary Care Center.
Oh SJ; Tashjian VC; Mirocha J; Nagar M; Mathur R; Lin E; Chua KS; Rezaie A; Pimentel M; Pichetshote N
Dig Dis Sci; 2019 Jan; 64(1):182-188. PubMed ID: 30324554
[TBL] [Abstract][Full Text] [Related]
2. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
[TBL] [Abstract][Full Text] [Related]
3. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
[TBL] [Abstract][Full Text] [Related]
4. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
5. Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome.
Vicari E; Salemi M; Sidoti G; Malaguarnera M; Castiglione R
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29099760
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic treatment of constipation-predominant irritable bowel syndrome.
Pimentel M; Chang C; Chua KS; Mirocha J; DiBaise J; Rao S; Amichai M
Dig Dis Sci; 2014 Jun; 59(6):1278-85. PubMed ID: 24788320
[TBL] [Abstract][Full Text] [Related]
7. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
[TBL] [Abstract][Full Text] [Related]
8. Rifaximin for the treatment of irritable bowel syndrome.
Cremonini F; Lembo A
Expert Opin Pharmacother; 2012 Feb; 13(3):433-40. PubMed ID: 22251066
[TBL] [Abstract][Full Text] [Related]
9. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.
Bae S; Lee KJ; Kim YS; Kim KN
J Korean Med Sci; 2015 Jun; 30(6):757-62. PubMed ID: 26028929
[TBL] [Abstract][Full Text] [Related]
10. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM; Sayuk GS
Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
[TBL] [Abstract][Full Text] [Related]
11. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea.
Lacy BE; Gagnon-Sanschagrin P; Heimanson Z; Bungay R; Bellefleur R; Guérin A; Bumpass B; Borroto D; Joseph G; Dashputre AA
Adv Ther; 2024 Jun; 41(6):2253-2266. PubMed ID: 38619720
[TBL] [Abstract][Full Text] [Related]
12. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.
Meyrat P; Safroneeva E; Schoepfer AM
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1084-93. PubMed ID: 23066911
[TBL] [Abstract][Full Text] [Related]
14. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation.
Schey R; Rao SS
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):461-4. PubMed ID: 21780893
[TBL] [Abstract][Full Text] [Related]
15. Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study.
Safwat E; Salah M; Hussein H
Arab J Gastroenterol; 2020 Dec; 21(4):273-277. PubMed ID: 32928705
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
Kane JS; Ford AC
Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
[TBL] [Abstract][Full Text] [Related]
17. Novel pharmacological therapies for irritable bowel syndrome.
Corsetti M; Whorwell P
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):807-15. PubMed ID: 26907518
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
20. ACG Clinical Guideline: Management of Irritable Bowel Syndrome.
Lacy BE; Pimentel M; Brenner DM; Chey WD; Keefer LA; Long MD; Moshiree B
Am J Gastroenterol; 2021 Jan; 116(1):17-44. PubMed ID: 33315591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
